What is the most appropriate induction regimen for a heart transplant patient with a negative panel reactive antibodies and crossmatch?

In the context of a heart transplant patient with a negative panel reactive antibodies (PRA) and a negative crossmatch, the use of an induction regimen can enhance the patient’s chances of a successful transplant by providing immunosuppression upfront. Methylprednisolone with basiliximab is an appropriate induction regimen in this scenario because it combines the immediate high-dose steroid effect of methylprednisolone, which helps prevent acute rejection, with basiliximab, an interleukin-2 receptor antagonist that selectively blocks T-cell activation.

This regimen is particularly beneficial for patients with a negative PRA and crossmatch because they exhibit lower immunological risk, allowing them to benefit from a less intensive but effective induction strategy. The combined use of these agents offers a balanced approach to immunosuppression that minimizes the risk of acute cellular rejection while avoiding the intense immunosuppression that could lead to higher chances of complications such as infection or long-term organ damage.

The choice to avoid intensive induction therapy is supported by the patient's low immunological risk status. While antithymocyte globulin offers potent immune suppression, it may be excessive in this situation, where the risk of rejection is already low. Additionally, combining basiliximab with antithym